Conrad Fischer

11PUBLICATIONS

24CO-AUTHORS

Proteins and peptidesPharmacogenomicsAnimal protection (incl. pests and pathogens)Molecular medicineBiological adaptation

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (11)

Sort by Publication Date:

|Jun 16, 2026

2-Substituted oxazolyl and thiazolyl amino acids are suitable P1 surrogates for new SARS-CoV-2 main protease inhibitors.

|Dec 22, 2025

Screening apelin analogues and a small molecule agonist as effective cardiovascular therapeutics against reperfusion injury.

Anjalee Wijewardane, Kleinberg X Fernandez, Anran Zhang

|Aug 18, 2025

Structural insights into the nirmatrelvir-resistant SARS-CoV-2 M<sup>pro</sup> L50F/E166A/L167F triple mutant-inhibitor-complex reveal strategies for next generation coronaviral inhibitor design.

Conrad Fischer, Jimmy Lu, Marco J van Belkum

|Nov 20, 2024

Peptide Aldehydes Incorporating Thiazol-4-yl Alanine Are Potent In Vitro Inhibitors of SARS-CoV-2 Main Protease.

Jenson R Feys, Kyle Edwards, Michael A Joyce

|Nov 06, 2024

Assessment of optimized FRET substrates as universal corona- and picornavirus main protease substrates for screening assays.

Conrad Fischer, Tayla J Van Oers, Marco J van Belkum

|Aug 30, 2024

A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (M<sup>pro</sup>) of SARS-CoV-2 and MERS-CoV.

Pu Chen, Tayla J Van Oers, Elena Arutyunova

Pageof 2

Frequent Collaborators

John C Vederas

M Joanne Lemieux

Tess Lamer

Marco J van Belkum

Tayla J Van Oers

Michael A Joyce

Wayne Vuong

Muhammad Bashir Khan

Justin Shields

Ryan T McKay

Frequent Collaborators

John C Vederas

M Joanne Lemieux

Tess Lamer

Marco J van Belkum